Sarepta Therapeutics Inc., a leader in precision genetic medicine, has announced new equity awards as part of its 2024 Employment Commencement Incentive Plan. On June 30, 2025, the company granted equity awards to 53 newly hired employees. These awards include options to purchase 22,016 shares of Sarepta's common stock and 317,317 restricted stock units (RSUs). The options are priced at $17.10 per share, matching the closing price of Sarepta's stock on the grant date. The options will vest over four years, with an initial 25% vesting after one year and the remainder vesting monthly. Similarly, the RSUs will vest annually over four years, contingent upon continued employment.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。